Want to see ZVSA full AI Analyst Report?
ZyVersa Therapeutics (ZVSA) Stock Statistics & Valuation Metrics
Total Valuation
ZyVersa Therapeutics has a market cap or net worth of $8,096.00. The enterprise value is $2.52M.
- Market Cap
- $8,096.00
- Enterprise Value
- $2.52M
Share Statistics
ZyVersa Therapeutics has 8,095,921 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 8,095,921
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
ZyVersa Therapeutics’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.05%.
- Return on Equity (ROE)
- 0.00
- Return on Assets (ROA)
- -0.07
- Return on Invested Capital (ROIC)
- 0.05%
- Return on Capital Employed (ROCE)
- 0.00
- Revenue Per Employee
- 0
- Profits Per Employee
- -4.16M
- Employee Count
- 6
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of ZyVersa Therapeutics is -0.00. ZyVersa Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.00
- PB Ratio
- -0.57
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.00
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, ZyVersa Therapeutics had revenue of 0 and earned -24.95M in profits. Earnings per share was -4.18.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -6.84M
- Pretax Income
- -25.80M
- Net Income
- -24.95M
- EBITDA
- -25.29M
- Earnings Per Share (EPS)
- -4.18
Cash Flow
In the last 12 months, operating cash flow was -2.62B and capital expenditures 0, giving a free cash flow of -2.62B billion.
- Operating Cash Flow
- -2.62B
- Free Cash Flow
- -2.62B
- Free Cash Flow per Share
- -0.32
Dividends & Yields
ZyVersa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -32376985.28%
- Earnings Yield
- -302.48%
Stock Price Statistics
- Beta
- 1.61
- 52-Week Price Change
- -66.67%
- 50-Day Moving Average
- 0.09
- 200-Day Moving Average
- 0.16
- Relative Strength Index (RSI)
- 23.25
- Average Volume (3m)
- 11.38K
Important Dates
ZyVersa Therapeutics upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 24, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
ZyVersa Therapeutics as a current ratio of 0.03, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.03
- Quick Ratio
- 0.03
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 4.02
- Interest Coverage Ratio
- -13.34
Taxes
In the past 12 months, ZyVersa Therapeutics has paid -851.66K in taxes.
- Income Tax
- -851.66K
- Effective Tax Rate
- 0.03
Enterprise Valuation
ZyVersa Therapeutics EV to EBITDA ratio is -36.34, with an EV/FCF ratio of -0.34.
- EV to Sales
- 0.00
- EV to EBITDA
- -36.34
- EV to Free Cash Flow
- -0.34
- EV to Operating Cash Flow
- -0.34
Balance Sheet
ZyVersa Therapeutics has $302.66M in cash and marketable securities with $1.20B in debt, giving a net cash position of -$897.34M billion.
- Cash & Marketable Securities
- $302.66M
- Total Debt
- $1.20B
- Net Cash
- -$897.34M
- Net Cash Per Share
- -$110.84
- Tangible Book Value Per Share
- -$1.74
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for ZyVersa Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 57.26%
Scores
- Smart Score
- ―
- AI Score
- 40
